SARS-CoV-2 Neutralising Antibody Tests
Measuring neutralising antibodies to Wild Type (Wuhan), Delta & Omicron variants following vaccination or natural infection
Accurate indicator of protective immunity against SARS-CoV-2 variants
The Randox CE marked SARS-CoV-2 Wild Type Surrogate Virus Neutralisation Assay (EV4454) and Delta SARS-CoV-2 Surrogate Virus Neutralisation Assay (EV4477) detect antibodies that block interaction of the spike protein receptor-binding domain (RBD) and angiotensin-converting enzyme 2 (ACE2). Randox Laboratories currently have in development an assay designed to detect antibodies against SARS-CoV-2 Omicron variant (EV4490).
Rapid, high throughput tests that measure neutralising antibodies against circulating SARS-CoV-2 variants are of significant interest to Clinical, Pharmaceutical, Government and Research organisations. Vaccine breakdown is of growing concern globally with the emergence of SARS-CoV-2 variants such as the now dominant Delta & Omicron strains. Randox have available innovative testing solutions to accurately measure protection against infection and to identify individuals where booster vaccination is required. This can help reduce infection rates and onward virus transmission by ensuring sufficient levels of herd immunity.
|Wild Type SARS-CoV-2 Surrogate Virus Neutralisation Assay||EV4454|
|Delta SARS-CoV-2 Surrogate Virus Neutralisation Assay||EV4477|
|Omicron SARS-CoV-2 Surrogate Virus Neutralisation Assay||EV4490|
|Evidence Investigator Analyser||EV3602|
Specificty of 100% and sensitivity of 98% compared ro coventional virus neutralisation tests
Semi-automated solution suitable for medium to high throughput testing
Direct sample addition to biochip well. No off-board sample incubation required
Results available in 1.5 hours without the need for biosafety level 3 cabinet
Limited sample volume requirements
Comprehensive immunoassay and molecular test menu available
Randox Clinical Laboratory Service (RCLS)
RCLS specialise in offering an esoteric biomarker testing service, utilising the experience and knowledge Randox has built over 40 years of producing high quality in vitro diagnostics.
RCLS strive to provide a clinical laboratory testing service to meet the time sensitive, bespoke requirements of research and clinical trial projects globally.
Accredited laboratory service
Cost effective solution
Offers greater flexibility
Want to know more?
Contact us or visit our COVID-19 Monitoring & Management page